A distinguishing feature of Pseudomonas aeruginosa isolates from cystic fibrosis (CF) patients is their mucoid, exopolysaccharide alginate-overproducing phenotype. One mechanism of conversion to mucoidy is based on mutations in the algU mucABCD cluster, encoding the stress factor AlgU and its regulators. However, conversion to mucoidy in laboratory strains can be achieved via mutations in other chromosomal sites. Here, we investigated mechanisms of the emergence of mucoid P. aeruginosa in CF by analyzing the status of mucA in a collection of mucoid P. aeruginosa isolates from 53 CF patients. This negative regulator of algU, when inactivated under laboratory conditions, causes conversion to mucoidy. The overall frequency of mucA alterations in mucoid CF isolates was 84%. Nucleotide sequence analyses revealed that the majority of the alterations caused premature termination of the mucA coding sequence. Comparison of paired nonmucoid and mucoid P. aeruginosa isolates from three CF patients indicated the presence of mucA mutations only in the mucoid strains. Interestingly, mucoid P. aeruginosa isolates from urinary tract infections also had mutations in the mucA gene. Clearance of CF isolates from the murine lung was investigated in an aerosol infection model with C57BL/6J, BALB/c, and DBA/2NHsd mice. Two CF strains, selected for further study based on the dependence of their alginate production on the concentration of salt in the medium, were used to examine the effects of mucoidy on pulmonary clearance. Statistically significant improvement in recovery from the murine lung of viable mucoid P. aeruginosa cells relative to the nonmucoid bacteria was observed in the majority of mouse strains tested. Collectively, the results reported here suggest that mucA is most likely the preferential site for conversion to mucoidy in CF and that alginate overproduction in mucA-mutant P. aeruginosa improves its resistance to the innate clearance mechanisms in the lung.
Pseudomonas aeruginosa is an opportunistic pathogen causing chronic respiratory infections in cystic fibrosis (CF) patients (14) . P. aeruginosa is also a common agent of urinary tract infections (UTIs) and can cause fatal infections in burned or neutropenic patients (2) . The most prominent feature of P. aeruginosa infecting CF patients is its conversion into the mucoid, exopolysaccharide alginate-overproducing phenotype (14) . This phenomenon has been associated with the establishment of the chronic phase of respiratory infections in CF (30) . Based on in vitro analyses, overproduction of alginate by P. aeruginosa is believed to have several effects, including inhibition of phagocytosis (36, 39) , protection from reactive oxygen intermediates (22, 37) , and a number of biofilm-related phenomena (21) . However, the comprehensive role of mucoidy in pathogenesis has not been defined. Earlier clearance studies with animal models have failed to confirm unequivocally the possibility that mucoid strains have a selective advantage in the respiratory tract (1, 41) . Nevertheless, significant attention has been given to the elucidation of the genetic mechanism of conversion to mucoidy (44) . In a series of recent studies (5, 24, 25) , such processes have been delineated at the molecular level with laboratory strains and have been tested with only a limited number of CF isolates.
Based on classical genetic studies by Govan and colleagues (12) , several mutations (termed muc) responsible for spontaneous conversion to mucoidy in laboratory strains have been mapped to at least two loci on the P. aeruginosa chromosome (Fig. 1A) . One such site (represented by the muc-23 mutation [ Fig. 1A] ) has been mapped between hisI at 69 min and proB at 71 min, while the other major locus (represented by the muc-22 mutation) has been found to be cotransducible with the pruAB marker at 67.5 min (11) . More recent analyses have permitted a detailed characterization of the latter site, which consists of a cluster of five genes, algU mucABCD (Fig. 1B) (5, 23, 25) . The first gene in this cluster, algU (alternative name, algT [7] ), encodes the P. aeruginosa equivalent of the extreme heat shock sigma factor E in enteric bacteria (45) and appears to be the principal positive regulator of mucoidy. The downstream genes, mucABCD, have been shown to negatively regulate AlgU activity (35) ; individual inactivation of mucA, mucB, or mucD in laboratory strains causes overt conversion to mucoidy (5, 24, 25) , while mucC has only mild effects (4) .
Spontaneous mutations in the mucA gene have been found upon conversion to the mucoid phenotype under laboratory conditions. Thorough genetic investigations have demonstrated that mucA alterations were responsible for the mucoid status in a subset of laboratory derivatives (25) . However, not all model strains of P. aeruginosa investigated thus far carry mutations in mucA, suggesting the existence of alternative pathways of conversion to mucoidy. For example, point mutations in mucA have been found in the few mucoid P. aeruginosa strains from CF patients examined to date (25) , but only a fraction of spontaneous mucoid P. aeruginosa isolates obtained in the laboratory carry mutations in mucA. This has cast some doubt on how important mucA is in CF, since the frequency of mucA mutations in mucoid strains including CF isolates remained unknown. In an effort to define the most common genetic alterations causing conversion to mucoidy in P. aeruginosa infecting CF patients, we initiated investigations with a collection of fresh CF isolates. Employing single-strand conformation polymorphism (SSCP) and automated DNA sequencing analyses, we determined here that the mutations in the mucA gene are found in the majority (84%) of mucoid isolates from CF patients. These findings suggest that mucA is the preferential site for conversion to mucoidy in vivo. We also initiated investigations of the role of conversion to mucoidy in an aerosol infection mouse model by using P. aeruginosa CF isolates and laboratory strains with characterized mucA mutations. We report here a differential clearance from murine lung of mucoid and nonmucoid strains, indicating improved survival of alginate-producing strains in the respiratory tract.
MATERIALS AND METHODS
Bacterial strains. Strains of P. aeruginosa originated from 53 CF patients from two geographic locations and represent independent isolates as determined by pyocin typing (unless indicated otherwise). Isolates CF52 to CF55 were obtained from one patient. All laboratory strains of P. aeruginosa used in this study were derivatives of the nonmucoid strain PAO381 (11) . PAO578I carries mucA22 and constitutively produces alginate (25) . PAO578II carries mucA22 and displays a medium-dependent mucoid phenotype due to the second site suppressor mutation sup-2 that occurred in the PAO578I background (5, 34) . PAO6888 is an algD::Gm r derivative of PAO578II constructed by chromosomal gene replacements.
Media and growth conditions. Escherichia coli was grown on Luria broth (LB) supplemented with kanamycin (25 g/ml) and gentamicin (10 g/ml) as required. P. aeruginosa was grown on Pseudomonas isolation agar (PIA; Difco) or in LB supplemented with NaCl (60, 100, or 300 mM), gentamicin (150 g/ml), carbenicillin (400 g/ml), or 1 mM isopropylthio-␤-D-galactopyranoside (IPTG) as required. All incubations, including those for aerosolization, were carried out at 37°C. For P. aeruginosa aerosol studies, bacteria were grown for 12 h and centrifuged at 3,000 ϫ g. The pellet was resuspended in 5 ml of cold 10 mM phosphate-buffered saline (pH 7.4) plus 1% Protease Peptone. The stock concentration was determined by plating, with the remaining 5 ml used for aerosolization. For SSCP assays, overnight cultures of CF isolates were centrifuged at 3,000 ϫ g and washed twice in cold phosphate-buffered saline, and chromosomal DNA was isolated with cetyltrimethylammonium bromide.
SSCP and automated DNA sequence analysis. SSCP detects mutations based on conformational differences between wild-type and mutant sequences. This is accomplished by denaturing relatively short DNA fragments followed by refolding of single-stranded DNA and analysis of conformational isomers by electrophoresis on native gels. To perform the SSCP analysis, the mucA gene was subdivided into the four arbitrary segments, I to IV. PCR fragments for each region were generated with the following 32 P-radiolabeled oligonucleotides: I, UL22 (5ЈAGCCTGACACAGCGGC3Ј) and UR17 (5ЈTCGTCGGCCAGGG CAG3Ј); II, UL23 (5ЈGCGCGGTCCGTCATGC3Ј) and UR33 (5ЈCAGGGCG TCGTTCTGG3Ј); III, UL8 (5ЈCGGTGACCCTGGCGGT3Ј) and UR18 (5ЈCG GGTATCGCTGGACG3Ј); and IV, UL20 (5ЈCGTGCTGGCCGGCTAC3Ј) and UR34 (5ЈCAGGGAGGTGGTGCGC3Ј). The PCR products were diluted 1:50 in 0.1% sodium dodecyl sulfate-10 mM EDTA (pH 8.0) and then 1:2 in denaturing dye (48% formamide, 25% [wt/vol] bromophenol blue, 25% [wt/vol] xylene cyanol, 10 mM EDTA [pH 8.0]). Samples were heated to 80°C for 5 min, with 2 l immediately loaded on a 0.5ϫ MDE gel (FMC). Gels were electrophoresed (6 W) at room temperature in 0.6ϫ TBE (100 mM Tris, 100 mM boric acid, 2 mM EDTA [pH 8.0]). Radiolabeled bands were detected by autoradiography at Ϫ70°C. Standard automated DNA sequence technology was used to determine the alterations in mucA.
Gene replacements and genetic complementation. pHYDGX, a suicide plasmid used for inactivation of algD on the chromosome, was constructed by placing the 11-kb HindIII fragment from pVD2X (6) into the HindIII site of pCMobB (27) . The XhoI xylE gene fragment was replaced with the Gm r XhoI fragment from pKI11G (16) . The homologous recombination between the insert of the plasmid pHYDGX and the chromosome was carried out as previously described (5) . Triparental conjugation with pRK2013 as the helper plasmid was used to introduce pHYDGX into PAO578II, and Gm r exconjugants were selected on PIA supplemented with gentamicin. Gm r Cb s recombinants were identified by replica plating. Gene replacements were confirmed by Southern blot analysis. The plasmids pVDtac24 and ptac-mucA ϩ and complementation of the chromosomal mucA alleles have been previously described (25) .
Animal aerosol infection model. Three mouse strains, BALB/c (Jackson Laboratory, Bar Harbor, Maine), C57BL/6J (Jackson Laboratory), and DBA/2NHsd (Harlan-Sprague Dawley, Indianapolis, Ind.), were used. Mice (8 weeks old) were exposed to P. aeruginosa aerosols in groups of five to eight animals in an inhalation exposure system (Glas-Col) for 30 min as described elsewhere (43) . Following nebulization of bacteria, cloud decay for 15 min, and a subsequent 15-min decontamination by UV irradiation, mice were removed from the inhalation chamber. The animals were euthanized with CO 2 either immediately for determination of the initial deposition of bacteria or 4 h postinfection. P. aeruginosa CFU were determined in lung homogenates by plating.
Alginate and TNF-␣ assays. Determination of uronic acid (alginate) was performed as previously described (19) . Levels of tumor necrosis factor alpha (TNF-␣) in lung tissue homogenate were determined 4 h postexposure by the Quantikine M mouse TNF-␣ immunoassay (R&D Systems).
Statistical analysis. SuperANOVA (analysis of variance) software (version 1.11; Abacus Concepts) was used to perform all statistical analyses (analysis of variance and Fisher's protected least-significant-difference post hoc test).
RESULTS
Mutations in the mucA gene in mucoid P. aeruginosa isolates from CF patients. To determine the frequency of mutations occurring in the mucA gene among mucoid P. aeruginosa isolates from CF patients, a collection of 55 CF strains was examined. The majority (53 strains) were isolated from different CF patients. All strains were characterized by pyocin typing, and only those isolates that differed by this criterion (unless specified otherwise) were included in further study. The mucA (5, 25) and in the majority of mucoid CF isolates (this work). Inactivation of mucC (shaded circle) has no overt phenotype, except in combination with other muc mutations when it augments their effects (4). Half arrows show oligonucleotides used to generate fragments corresponding to the regions of mucA used for SSCP analysis (I, II, III, and IV); numbers are relative to the previously established nomenclature (25) . (C) Model depicting how mutations in mucA ϩ cause conversion to mucoidy in CF strains. In wild-type nonmucoid cells and under normal physiological conditions, AlgU is inhibited by MucA (35) . Inactivation of mucA in CF isolates releases AlgU, leading to increased expression of the response regulator algR. AlgU and AlgR cooperate to activate the key alginate biosynthetic gene algD, causing the mucoid phenotype.
sequence was subdivided into four arbitrary segments suitable for SSCP analysis (regions I, II, III, and IV) (Fig. 1B) . Based on SSCP analysis (Fig. 2) , the overall frequency of mucA mutations in CF isolates was 84%. The majority of altered SSCP patterns (77%) were found ( Fig. 2C) within the third quarter of the mucA sequence (Fig. 2B , region III). Additional alterations (7%) were found in other segments (regions I, II, and IV) ( Fig. 1B and 2A , B, and C). DNA sequencing analysis ( Fig.  3 ) was carried out on a subset of 41 strains which showed representative mucA alterations by SSCP. The most frequently observed mucA mutations fell into two categories: frameshifts and C-to-T transitions which resulted in stop codons ( Table 1) . The most common mutation (observed in 25% of the strains carrying mucA mutations ( Fig. 3 and Table 1 ) was a deletion of a G within the homopolymeric stretch of five G residues located between positions 429 and 433 of the mucA coding sequence (436 and 440 relative to the ribosomal binding site of mucA [Fig. 3] ) and was designated mucA⌬G440 (residue 440 chosen arbitrarily) according to the previously established nomenclature (25, 44) . Interestingly, this mutation has also been identified in mucoid laboratory strains and is identical to mucA22, one of the first mapped (12) and characterized (25) muc alleles at 67.5 min. Homopolymeric runs of nucleotides have been identified as the basis for frameshift mutations in some phase variation systems (17) , and the relatively high frequency of mucA⌬G440 alleles among mucoid CF isolates may reflect similar processes. Another frequently encountered alteration was a C-to-T transition at position 362 ( Fig. 3 ) generating a stop codon in place of a glutamine codon. In addition, several less-prominent clusterings of mutations were observed (Fig. 3) . Since the vast majority of the characterized alleles in CF isolates represented truncated versions of mucA, it was concluded that these changes were most likely not polymorphisms but mutations associated with the mucoid phenotype of the CF strains. This notion is supported by previously published studies with allelic replacements (with the most typical allele, mucA⌬G440) in laboratory strains, which have demonstrated that a loss of mucA function causes conversion to mucoidy (25) . To experimentally verify this conclusion, a selection of CF strains with mucA alleles characterized in this work, CF60 (the 5Ј-most mutation), CF40 (carrying an insertion of a T at position 295 and the mucA⌬G440 mutation), and CF53
FIG. 2.
Representative sample of SSCP analyses of the mucA gene from clinical mucoid P. aeruginosa isolates. The strains were initially screened for SSCP differences in region III (C), in which the majority of the observed alterations were found. Strains not displaying changes in region III were further systematically analyzed for potential alterations in regions I, II, and IV (A, B, and D, respectively). The PAO1 pattern is shown as a standard for each region. Two bands were detected by SSCP in CF16 (carrying a 42-bp deletion); only the top band is shown in the section of the gel displayed here. With the exceptions indicated in the text and Table 1 (e.g., strain CF40), isolates carrying mutations in region III were not routinely investigated for additional changes in other regions of mucA.
FIG. 3.
Mutations in the mucA gene from mucoid clinical isolates of P. aeruginosa. Shown is the mucA sequence of PAO1; differences observed in the clinical strains are indicated as follows: CF, mucoid isolates from CF patients; UT, mucoid urinary tract isolates; boldface letters, insertions, deletions, or substitutions of indicated nucleotides; inverted triangles, insertions; overscored nucleotides, positions of single nucleotide deletions (for mucA⌬G440 all five G residues are overscored because of the ambiguity); ⌬, frameshifts; ⌬Start and ⌬Stop, beginnings and ends, respectively, of large deletions; underlined triplets, stop codons brought into frame via upstream frameshift mutations (TGA 294 , TGA 396 , TGA 450 , and TGA 487 [also see Table 1 ]) or resulting from C-to-T transitions; arrow underneath the sequence, 8-bp duplication in CF42 (identical to the duplication previously seen in the laboratory strain PAO568 [25] ); and overhead arrows, long repeats demarcating the ends of the deletion in CF16.
(the 3Ј-most mutation, which is also one of the rare missense changes observed in mucA), were subjected to genetic complementation by plasmid-borne mucA ϩ . All strains tested displayed a nonmucoid phenotype when complemented by mucA ϩ , although some variability in dependence of the complementation on induction of ptac-mucA ϩ by IPTG was observed, possibly reflecting differences between the mutant mucA alleles tested (Table 2 ). These findings are in keeping with the previously reported gene replacements on the chromosome of laboratory strains (5, 25) and strongly suggest that mucA is the site causing conversion to mucoidy in the CF isolates tested. Collectively, these observations strongly support the conclusion that mucA is the predominant site for P. aeruginosa conversion to mucoidy in CF.
Analysis of paired mucoid and nonmucoid P. aeruginosa strains from CF patients. Establishment of the chronic infection phase in patients with CF coincides with the conversion of P. aeruginosa to the mucoid phenotype (20, 30) . Since coexisting mucoid and nonmucoid strains can be found in some patients, it was of interest to compare mucoid and nonmucoid strains isolated from the same lung. For this analysis, three pairs of CF isolates obtained from three different patients were characterized as having indistinguishable pyocin patterns when the paired mucoid and nonmucoid strains were compared. For all three paired strains, the mucoid P. aeruginosa CF isolate had an apparent region III SSCP pattern change whereas its nonmucoid counterpart did not have such a change (Fig. 4A) . The mucA region III from the mucoid isolates CF45 and CF46 was sequenced, and the specific mutations were identified (mucA⌬G440 and mucAC362T, respectively) ( Table 1) . Based on the SSCP patterns, the alteration in CF44 appeared identical to that in CF45 (mucA⌬G440) and was not sequenced. These findings are consistent with the interpretation that mutations in the mucA gene occurred in the mucoid isolate, although a parent-progeny relationship between nonmucoid and mucoid strains could not be ascertained.
Multiple mucoid P. aeruginosa isolates from a single CF patient may carry different mucA mutations. It has been observed that individual CF patients can carry a heterogeneous population of mucoid isolates (32) . To assess the status of the mucA gene in multiple mucoid strains colonizing the same patient, we examined mucA in a set of four mucoid strains (CF52, CF53, CF54, and CF55) isolated from a single CF patient. First, SSCP analyses of region III of mucA suggested that only one strain (CF55) had a mutation in this region (Fig.  4B) . However, SSCP and sequence analyses of other regions of mucA indicated that three of the four strains analyzed (with the exception of CF54) contained alterations in the mucA gene (Table 1 ). All strains with detectable mutations in mucA had different alterations: CF52 had a C3T transition generating a termination codon at 431, CF53 had a C3T transition at 560, and CF55 had a frameshift mutation (⌬G at 440). This suggests that multiple mucoid isolates of P. aeruginosa present in one patient can emerge independently or have independent origins, as evidenced by the different mucA alleles observed.
Mucoid P. aeruginosa isolates from UTIs and mutations in mucA. The association of mucoid P. aeruginosa strains with the respiratory tracts of patients with CF has been well documented (14) . However, mucoid strains of P. aeruginosa can also be isolated from other infection sites, albeit at a lower frequency. For example, mucoid P. aeruginosa strains have been noted in UTIs (26) . To determine if mutations in the mucA gene can be selected in additional infection sites, we examined four mucoid urinary tract isolates. SSCP patterns in three of these strains indicated changes in mucA (Fig. 4C) . The DNA sequences were determined for two of these strains (UT49 and (23) . Based on SSCP patterns, strains CF10, CF17, CF38, CF39, and CF44 appeared identical to PAO578; CF36 and CF37 appeared identical to CF25; and CF11 appeared identical to CF9. SSCP patterns of strains CF12, CF18, CF24, CF27, CF30, CF32, CF47, and CF54 gave no indications of a change in mucA. These strains were not subjected to sequence analysis.
b ⌬G at 440 is an arbitrary choice of a G residue within the homopolymeric stretch of five G's from 436 to 440. An entry in parentheses represents the second (downstream) nonsense mutation.
c Termination codon generated at the site of the alteration or placed in frame because of a frameshift.
d Change relative to the PAO1 sequence of mucA. e Replacement of coding sequence between V 95 and A 144 due to insertion of T 295 and ⌬G440. UT50) and showed the presence of a relatively large deletion in region III of mucA in UT50 (Fig. 2 and 4C and Table 1 ) and a smaller deletion in region II of mucA in UT49 ( Fig. 2 and Table 1 ). These results suggest that mucA mutations in P. aeruginosa can cause mucoidy in infection sites other than the CF lung.
Differential clearance of mucoid and nonmucoid P. aeruginosa strains from the murine lung. A respiratory infection model in mice that uses P. aeruginosa aerosols has recently been developed to investigate inflammatory processes during extended exposure to this pathogen (43) . Here, we employed the same aerosol delivery technology (see Materials and Methods) to investigate how the mucoid or nonmucoid status of P. aeruginosa affects its pulmonary clearance by using a select number of characterized CF isolates and laboratory mucA mutants. In preliminary analyses, several nonmucoid and mucoid CF isolates were compared, but the clearance was highly variable even among nonmucoid strains. To overcome the problem of the complex and unknown nature of the heterogeneity among clinical strains, we resorted to the use of a subset of CF isolates which contained muc mutations but whose mucoid or nonmucoid status could be manipulated, depending on the growth conditions. One such CF isolate, CF40 (mucA⌬G440), displayed a mucoid phenotype only in the presence of increased salt concentrations. Aerosolization of CF40 after growth in the presence of 100 mM NaCl (optimal for alginate production by this strain) resulted in 45.2% Ϯ 4.2% survival in the lung at 4 h postinfection in C57BL/6J mice. In the absence of alginate induction (no salt added to the growth medium), CF40 displayed a statistically significant reduction in survival (14.8% Ϯ 0.7%) (P ϭ 2.1 ϫ 10 Ϫ2 [ Table 3 ]). Another CF isolate (CF45) with alginate production dependent upon the concentration of salt in the medium was also tested. This strain displayed optimal induction of alginate production when grown in the presence of 60 mM NaCl. Aerosol challenge of C57BL/6J mice with CF45 grown in the presence of 60 mM NaCl, conditions which rendered this strain mucoid, resulted in 25.1% Ϯ 4.4% survival at 4 h ( Table 3) . Challenge with the same strain, grown in the absence of salt (which rendered CF45 nonmucoid), resulted in 7.5% Ϯ 1.3% survival at 4 h in C57BL/6J mice, which was lower than that of the mucoid form of the same strain (P ϭ 4.0 ϫ 10 Ϫ2 ) ( Table 3 ). In both cases tested, the mucoid status (or growth on high salt) was associated with a higher rate of survival in the lung.
Alginate production in some muc derivatives of the standard genetic strain PAO is also dependent on the concentration of salt in the medium. One such strain, PAO578II, which remains nonmucoid unless salt concentrations are adjusted to higher levels, displayed 21.0% Ϯ 3.3% survival in C57BL/6J mice when grown under standard conditions (Table 3) . Upon increasing the salt concentration to a level (300 mM) coinciding with the induction of alginate production in PAO578II, there was an increase in survival in the mouse lung (43.7% Ϯ 4.5%; P ϭ 1.6 ϫ 10 Ϫ2 ). In the presence of 60 mM NaCl in the growth medium, a concentration which was not sufficient to render PAO578II mucoid, there was no significant change in pulmonary clearance of this strain relative to the growth in the absence of added salt (P ϭ 0.86).
To further determine if the observed improvement in survival of the strains tested was due to the induction of mucoidy, the key alginate biosynthetic gene algD (6) was inactivated in PAO578II. Growth of the resulting strain, PAO6888 (mucA22 FIG. 4 . SSCP analysis of mucA region III in paired nonmucoid (NM) and mucoid (M) P. aeruginosa isolates (A), multiple independent mucoid isolates from the same CF patient (B), and mucoid isolates from UTIs (C). (A) C1272 and CF44, C1287 and CF45, and C1319 and CF46 are paired nonmucoid and mucoid strains (C followed by a number, nonmucoid; CF44, CF45, and CF46, mucoid). Each pair was isolated from a different CF patient. (B) Region III from multiple mucoid P. aeruginosa strains (differing by pyocin typing) isolated from one patient. (C) SSCP analysis of the mucA gene from mucoid P. aeruginosa urinary tract isolates. algD::Gm r Alg Ϫ ), in the presence of 300 mM NaCl (where it remained nonmucoid because of the algD mutation) resulted in a low rate of survival, somewhat below the levels observed with PAO578II (algD ϩ ) grown in the absence of salt (Table 3 ; P ϭ 5.0 ϫ 10 Ϫ1 ). In addition, when C57BL/6J mice were challenged with the nonmucoid strain PAO381 (parental to PAO578II), grown in the presence of added salt, no significant change in pulmonary clearance was observed (Table 3) . Collectively, these findings suggest that the observed reduction in lung clearance of PAO578II upon addition of salt can be attributed to mucoidy rather than to induction of alternative defense mechanisms. In further confirmation of the role of alginate production in improved survival of P. aeruginosa in the murine lung, the strain PAO578I was tested (PAO578I is isogenic with PAO381 and PAO578II but is constitutively mucoid under all conditions), and it displayed improved survival relative to its parental strain, PAO381 (38.9% Ϯ 8.9% for PAO578I versus 20.5% Ϯ 5.6% and 24.8% Ϯ 4.8% for PAO381; P ϭ 1.0 ϫ 10 Ϫ4 [ANOVA]). These data strongly suggest that production of alginate reduces pulmonary clearance of P. aeruginosa in the murine lung.
Analysis of P. aeruginosa clearance in different strains of mice. It has been suggested that the susceptibility to P. aeruginosa in mouse models of respiratory infections depends on the mouse strain used (29) . For example, BALB/c mice have been found to be more resistant to P. aeruginosa than DBA/2NHsd mice (29) , while C57BL/6J mice are considered to have an intermediate sensitivity to P. aeruginosa (28) . To examine whether the advantage of mucoid versus nonmucoid P. aeruginosa organisms observed in C57BL/6J mice can be detected in mice with different innate susceptibilities to P. aeruginosa, BALB/c and DBA/2NHsd mice were challenged with CF45 cells grown under conditions conducive to the mucoid or nonmucoid phenotype. In the DBA/2NHsd mouse, challenge with the mucoid form of CF45 resulted in a detectable increase in survival relative to challenge with the nonucoid CF45 strain (72.4% Ϯ 4.7% and 35.4% Ϯ 11.7%, respectively; P ϭ 1.0 ϫ 10
Ϫ4
).
When the isogenic strains PAO381 and PAO578I were compared in DBA/2NHsd, C57BL/6J, and BALB/c mice, a statistically significant decrease (P ϭ 4.0 ϫ 10 Ϫ4 [ANOVA]) in pulmonary clearance, coinciding with the production of alginate, was seen in all three mouse strains ( Table 3 ). The mucoid strain PAO578I displayed survival rates of 41.6% Ϯ 8.5%, 38.9% Ϯ 8.9%, and 17.2% Ϯ 0.6%, while the nonmucoid parental strain PAO381 had survival rates of 10.5% Ϯ 1.3%, 20.5% Ϯ 5.6%, and 3.7% Ϯ 0.8% at 4 h postinfection in BALB/c, C57BL/6J, and DBA/2NHsd mice, respectively (Table 3). In only one case examined (mucoid versus nonmucoid CF45 in BALB/c mice) were no statistically significant differences in clearance observed. These results indicate that with a single exception, various combinations of P. aeruginosa and mouse strains tested favored mucoid P. aeruginosa over the nonmucoid matching strain for survival in the murine lung.
P. aeruginosa clearance and TNF-␣ levels. We next wanted to assess whether the reduced clearance of mucoid strains could be attributed to potential differences in levels of proinflammatory cytokines induced by mucoid versus nonmucoid bacteria. Levels of TNF-␣, a cytokine implicated in promoting P. aeruginosa clearance from the murine lung (28), were measured in the lungs at the time of bacteriological evaluation. In all challenged animals, irrespective of the mucoid or nonmucoid status of the strain used, a significant increase in TNF-␣ was observed upon exposure to P. aeruginosa (2.4 to 13.9 ng/g of lung tissue 4 h postinfection) over the levels seen in unexposed animals (0.02 Ϯ 0.005 ng/g of lung tissue). Although overall TNF-␣ levels varied between the mouse and P. aeruginosa strains used (P ϭ 5 ϫ 10 Ϫ3 [ANOVA]), no statistically significant correlation between TNF-␣ levels and mucoid versus nonmucoid status could be observed in the majority of mice exposed to P. aeruginosa (P ϭ 0.46 [ANOVA] ). Overall, only in BALB/c mice exposed to mucoid and nonmucoid forms of CF45 was there a statistically significant decrease in TNF-␣ levels in animals infected with a mucoid P. aeruginosa strain (Table 4 ; P ϭ 2.5 ϫ 10 Ϫ2 [Fisher's protected least-significant a PAO578I is a constitutive mucoid derivative of PAO381. PAO578II is a derivative of PAO578I with a suppressor mutation (sup-2 [5, 34] ) which attenuates the mucoid phenotype and renders it dependent on the concentration of salt in the medium.
b Known alterations in mucA are listed. mucA22 and sup-2 have been previously described (25, 34) . c NaCl concentrations were optimized for maximal alginate production by individual CF isolates. d M and NM, mucoid phenotype and nonmucoid phenotype, respectively, on the medium used to grow P. aeruginosa for clearance studies (see Materials and Methods). Strain phenotypes on LB and PIA were as follows: CF45, NM (LB) and M (PIA); CF40, NM (LB) and M (PIA); PAO381, NM on both media; PAO578I, M on both media; PAO578II, NM (LB) and M (PIA).
e Survival at 4 h is expressed as the percentage of the initial CFU deposited in the lung. Initial bacterial depositions were as follows: BALB/c, 5.3 ϫ 10 5 to 3.7 ϫ 10 6 ; C57BL/6J, 2.2 ϫ 10 5 to 3.5 ϫ 10
6
; and DBA/2NHsd, 7.0 ϫ 10 5 to 9.5 ϫ 10 6 . The numbers of bacteria remaining were determined by plating of total lung homogenate after 4 h. n, number of animals per mouse strain used in determining initial deposition and 4-h clearance. P values (t test) were as follows: DBA/2NHsd, P ϭ 4.33 ϫ 10 Ϫ2 for the two forms of CF45 and P ϭ 3.91 ϫ 10 Ϫ2 for PAO381 versus PAO578I; C57BL/6J, P ϭ 2.10 ϫ 10 Ϫ3 for the two forms of CF40, P ϭ 1.92 ϫ 10 Ϫ2 for the two forms of CF45, P ϭ 1.64 ϫ 10 Ϫ4 for PAO381 versus 578I, P ϭ 1.57 ϫ 10 Ϫ2 for PAO578II and PAO578II at 0.3 M NaCl, and P ϭ 3.59 ϫ 10 Ϫ3 for PAO578II at 0.3 M NaCl and PAO6888; BALB/c, P ϭ 2.20 ϫ 10 Ϫ2 for PAO381 versus PAO5781. ND, not determined. difference test]). However, this was also the only case in which a mucoid strain did not show a statistically significant reduction in clearance over the paired nonmucoid control (Table 3 ; P ϭ 0.36). It is worth noting that C57BL/6J mice exposed to mucoid CF40 and PAO578II displayed the lowest levels of TNF-␣ (Table 4) , coinciding with the highest rates of survival in this mouse strain (Table 3) . However, statistically significant parallels between reduced TNF-␣ levels and survival were not observed for the whole set of data (P ϭ 0.76 [ANOVA]). Moreover, the highest survival rate of P. aeruginosa recorded in this study (72% [Table 3 ]), which was observed in DBA/2NHsd mice, was not associated with any extreme values for TNF-␣ (Table 4) . Thus, no apparent correlations could be made between TNF-␣ levels and survival rates of mucoid versus nonmucoid strains of P. aeruginosa in the murine lung at the time point examined. These findings suggest that the observed reduction in clearance of mucoid strains cannot be attributed to effects on TNF-␣ levels. In conclusion, the observed advantage of strains expressing the mucoid phenotype may be at least partially independent of the levels of inflammatory cytokines provoked by the infection.
DISCUSSION
In this study, we have identified the mucA gene as the major site of genetic changes causing conversion of P. aeruginosa to mucoidy in CF patients. Alterations in the mucA gene have been detected at a high frequency (84%) in CF strains. The majority of mucA alterations result in a truncation of the mucA gene via introduction of premature stop codons, frameshifts, or other open reading frame disruptions. The nature of the mucA lesions in CF strains argues against the possibility that the detected alterations are simple polymorphisms. The complementation to nonmucoidy of the representative mucA CF mutants by a mucA ϩ gene further supports such conclusions. The interpretation that mucA lesions cause conversion to mucoidy in CF strains is consistent with the previously reported gene replacement studies (25) . In such studies, replacements of the chromosomal mucA ϩ gene with mutant mucA alleles (which included mucA22, the PAO equivalent of the most common CF allele, mucA⌬G440) resulted in conversion to mucoidy. It also appears that a strong selection for mucA mutants exists in the lungs of CF patients, explaining the higher frequency of mucA alterations among clinical mucoid strains than among spontaneous mucoid derivatives obtained in the laboratory. In this work, we have also addressed the role of the overproduction of alginate in the survival of P. aeruginosa in the lung. The subtle but statistically significant reduction in pulmonary clearance of mucoid strains in a mouse model of respiratory infection observed with CF isolates and isogenic mucoid and nonmucoid derivatives of PAO suggests increased resistance of the alginate-producing forms of P. aeruginosa to the innate defenses in the respiratory tract.
Although the mucA gene has received attention as a possible site of mutations causing conversion to mucoidy in P. aeruginosa (5), it has been a general belief that other mechanisms, besides inactivation of mucA, may also cause conversion to the mucoid phenotype. For example, early analyses of a collection of laboratory strains and a limited number of CF isolates have indicated that mucA may not be the only candidate for the major site of mutations causing mucoidy (5) . In keeping with this notion, other genes in the mucABCD cluster (5) and at least in one additional locus (11) on the P. aeruginosa chromosome, have been shown to represent potentially significant sites of mutations causing conversion to mucoidy. Based on the analyses reported here, mucA appears to be the most frequent site of mutations in strains infecting CF patients. Moreover, since the observed frequency of alterations in mucA (84%) is based on an SSCP assay, which does not necessarily permit detection of all mutations, this value should be taken as an underestimate of the incidence of mucA mutations in mucoid P. aeruginosa CF isolates. While the specific reasons for the apparent preponderance of mutations in mucA among clinical strains are not known at present, it is possible that mutations in other sites, albeit causing mucoidy (12) , confer some other disadvantages in vivo. Such effects may offset the benefits of alginate overproduction during infection but may not be critical for growth under laboratory conditions.
Mucoid P. aeruginosa strains can also be found in infection sites other than CF, including the urinary tract. The analyses of the mucA gene from mucoid P. aeruginosa urinary tract isolates have uncovered alterations similar to those observed in CF strains. Intriguingly, earlier reports comparing UTI and CF strains have indicated that P. aeruginosa isolates from CF and UTIs may have considerable phenotypic similarities (8, 26, 32) . It is not known whether and to what extent the selective pressures and clearance mechanisms are comparable in the two infection sites, but they seem to favor the emergence of mucoid strains via what appears to be a common conversion pathway. Furthermore, the presence of mucA mutations in UTI isolates confirms the notion that mucoid P. aeruginosa can be found under clinical conditions different from CF. It should also be mentioned that three different mucA SSCP band patterns were observed for region III in a preliminary analysis of P. aeruginosa immunotypes O1 to O20 (unpublished results). The reasons for these polymorphisms, which remain to be characterized, are currently not known, but they could reflect the history of these strains (which, to our knowledge, has not been described in the literature) in the context of the infections that served as their source.
It is worth noting that the process of mucA inactivation in mucoid CF isolates is random, with a number of possible outcomes leading to the loss of mucA function. The loss of lipopolysaccharide O side chains in clinical isolates of P. aeruginosa has also been reported to include random mutations (9) . Thus, the variations in expression of the two major exopolysaccharides of P. aeruginosa appear not to be based on programmed genetic events. In keeping with this notion, nonmucoid variants derived in vitro from mucoid mutants do not seem to represent direct reversions of mucA mutations (34) . However, the observed clustering of mutations at several locations within re- Ϫ3 for TNF-␣ levels (overall), 7.6 ϫ 10 Ϫ1 for TNF-␣ versus P. aeruginosa survival, and 4.6 ϫ 10 Ϫ1 for survival (Table 3 ) by mucoid (M) and nonmucoid (NM) P. aeruginosa strains versus TNF-␣. ND, not determined. gion III and other positions within mucA potentially reflects specific interactions with other participants in the control of AlgU activity (e.g., MucB and MucC). Work is in progress to define the functional domains of MucA and how MucA interacts with AlgU on one end and with MucB and MucC on the other. In this context, the collection of mutants described in this work is expected to assist the ongoing structure-function analyses of MucA.
In an earlier analysis comparing P. aeruginosa mucoid and nonmucoid strains (using a mucoid parent and its nonmucoid revertant), no differences in lung clearance of the strains tested were reported upon intratracheal instillation in guinea pigs (1) . In contrast, we find that pulmonary clearance from the murine lung in the infection model used here is affected by the mucoid or nonmucoid status of P. aeruginosa. It has also been reported that the susceptibility to P. aeruginosa infections differs between mouse strains (28) . In this study, we found that susceptibility to P. aeruginosa aerosol challenge in DBA/2NHsd, BALB/c, and C57BL/6J mice varies with the bacterial strain used (Table 3 ; P ϭ 3.6 ϫ 10 Ϫ2 [ANOVA]). Despite the increased levels of the proinflammatory cytokine TNF-␣ in each mouse strain exposed to P. aeruginosa, comparison of the TNF-␣ levels induced in BALB/c, C57BL/6J, and DBA/2NHsd mice revealed no statistically significant differences. It is possible that our findings are at variance with those in the previous reports (1, 28) because of the differences in bacterial strains, bacterial delivery (aerosol versus intratracheal instillation), and clearance analysis. Independent of these considerations, our results obtained with three different strains of mice suggest that alginate production improves the survival of P. aeruginosa in mouse lungs. Such differences may easily be missed or masked by other variables if the strains are not carefully matched and the aerosol delivery is not controlled with the utmost care. Furthermore, the known effects of initial bacterial deposition levels on the course of clearance (40) must be taken into account and controlled carefully.
Studies presented here and elsewhere (5, 35, 42 ) support the following model (Fig. 1C) for the role of mucA mutations in P. aeruginosa infections in CF. The high frequency of mucA mutations found in mucoid CF isolates strengthens the notion that alterations in mucA represent the major pathway leading to the conversion to the mucoid phenotype in the lungs of CF patients. In the initially colonizing nonmucoid cell, as illustrated in Fig. 1C , MucA binds to AlgU (15, 35) , preventing efficient transcription of the key alginate biosynthetic gene algD. Inactivation of mucA by spontaneous mutations, as observed in the CF isolates presented here, permits AlgU to transcribe the response regulator gene algR. AlgU and AlgR, in cooperation, activate algD (and possibly additional elements), leading to alginate overproduction and the mucoid phenotype. Based on the observed advantage of mucoid strains, as reflected in the improved survival rates relative to nonmucoid P. aeruginosa in the model of aerosol infection in mice employed in this work and further supported by the previously reported in vitro studies suggesting various protective attributes of alginate (21, 22, 30, 36, 37, 39) , it is possible to conclude that the mucoid phenotype may promote persistence of P. aeruginosa in the respiratory tract. Whether the roles of mucA mutations and contributions of alginate production to the pathogenesis of CF end with the effect of impeding pulmonary clearance of P. aeruginosa is currently not known (33) . Furthermore, it would be of interest to study the potential interplay between the mucoid phenotype in P. aeruginosa and the recently recognized host factors in CF, which fall into several categories: e.g., reduced sialylation of glycoconjugates and increased adhesion (46) , altered bactericidal properties of epithelial secretions ascribed to modified salt content (13, 38) , uptake by epithelial cells (31) , and endogenous or infection-dependent elevation of proinflammatory cytokines (3, 18) . Investigations are under way to address the effects of mucoidy in P. aeruginosa on the histopathology of the lung and production of inflammatory cytokines during prolonged exposure to the pathogen. These and additional studies may provide new information potentially critical for better control of respiratory infections in CF.
